Ceritinib is a second-generation ALK tyrosine kinase inhibitor with activity against several crizotinib-resistant ALK mutations, used in ALK-positive non-small cell lung cancer. Simson Pharma's Ceritinib reference standard and impurities support stability-indicating method development for this targeted lung-cancer therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Ceritinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.
